Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

No statistically significant change in MADRS total score was observed with solriamfetol vs placebo in the overall study population. Topline results were announced from a phase 3 trial evaluating ...

Compared with placebo, pitolisant 20 and 40 mg had a greater treatment response for residual excessive daytime sleepiness in patients with OSA treated with CPAP. Pitolisant reduces residual excessive ...

Compared with placebo, pitolisant 20 and 40 mg had a greater treatment response for residual excessive daytime sleepiness in patients with OSA treated with CPAP. Pitolisant reduces residual ...

Observers say married couples may experience greater levels of financial and emotional stress that hasten the onset of ...

Please provide your email address to receive an email when new articles are posted on . Using baseline scores as reference points, three measures of cognitive function improved more when patients ...

In a recent Managed Healthcare Executive K-Cast video series, R. Robert Auger, M.D., a psychiatrist and sleep specialist at the Mayo Clinic in Rochester, Minnesota, spoke about the diagnosis and ...

By Dr. Jaisingh Rajput, MD  Sleep is essential for heart health, but millions of Americans unknowingly suffer from sleep ...

Investigating Sunosi as a treatment for MDD patients with and without excessive daytime sleepiness (EDS), a phase 3, proof-of-concept study did not meet its primary endpoint, Axsome said Tuesday.

Discover the causes of snoring and explore possible treatment options for a better night’s sleep and improved health. Snoring is a common phenomenon. According to the American Academy of ...